BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 31025231)

  • 1. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
    Molin MD; Matthaei H; Wu J; Blackford A; Debeljak M; Rezaee N; Wolfgang CL; Butturini G; Salvia R; Bassi C; Goggins MG; Kinzler KW; Vogelstein B; Eshleman JR; Hruban RH; Maitra A
    Ann Surg Oncol; 2013 Nov; 20(12):3802-8. PubMed ID: 23846778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
    Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
    Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs".
    Matthaei H; Wu J; Dal Molin M; Shi C; Perner S; Kristiansen G; Lingohr P; Kalff JC; Wolfgang CL; Kinzler KW; Vogelstein B; Maitra A; Hruban RH
    Am J Surg Pathol; 2014 Mar; 38(3):360-3. PubMed ID: 24525507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.
    Yoshida K; Nagasaka T; Umeda Y; Tanaka T; Kimura K; Taniguchi F; Fuji T; Shigeyasu K; Mori Y; Yanai H; Yagi T; Goel A; Fujiwara T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1557-69. PubMed ID: 27095449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
    Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
    Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia.
    Singhi AD; McGrath K; Brand RE; Khalid A; Zeh HJ; Chennat JS; Fasanella KE; Papachristou GI; Slivka A; Bartlett DL; Dasyam AK; Hogg M; Lee KK; Marsh JW; Monaco SE; Ohori NP; Pingpank JF; Tsung A; Zureikat AH; Wald AI; Nikiforova MN
    Gut; 2018 Dec; 67(12):2131-2141. PubMed ID: 28970292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assessment of the GNAS mutation status in patients with intraductal papillary mucinous neoplasm of the pancreas.
    Ohtsuka T; Tomosugi T; Kimura R; Nakamura S; Miyasaka Y; Nakata K; Mori Y; Morita M; Torata N; Shindo K; Ohuchida K; Nakamura M
    Surg Today; 2019 Nov; 49(11):887-893. PubMed ID: 30879148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from McCune-Albright syndrome-associated intraductal papillary mucinous neoplasms: : GNAS-activating mutations in pancreatic carcinogenesis.
    Parvanescu A; Cros J; Ronot M; Hentic O; Grybek V; Couvelard A; Levy P; Chanson P; Ruszniewski P; Sauvanet A; Gaujoux S
    JAMA Surg; 2014 Aug; 149(8):858-62. PubMed ID: 24898823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Date K; Ohtsuka T; Fujimoto T; Tamura K; Kimura H; Matsunaga T; Mochidome N; Miyazaki T; Mori Y; Oda Y; Nakamura M; Tanaka M
    Ann Surg; 2017 May; 265(5):969-977. PubMed ID: 28398963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms.
    Kadayifci A; Atar M; Wang JL; Forcione DG; Casey BW; Pitman MB; Brugge WR
    Dig Endosc; 2017 Jan; 29(1):111-117. PubMed ID: 27514845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas.
    Tampakis A; Tampaki EC; Posabella A; Zettl A; Kouraklis G; von Flüe M; Guenin MO
    Pancreas; 2017 Jan; 46(1):e5-e7. PubMed ID: 27977634
    [No Abstract]   [Full Text] [Related]  

  • 20. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.